Siren, L.L.C. Denali Therapeutics Inc. Transaction History
Siren, L.L.C.
- $2 Trillion
- Q3 2024
A detailed history of Siren, L.L.C. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 834,028 shares of DNLI stock, worth $20.6 Million. This represents 1.21% of its overall portfolio holdings.
Number of Shares
834,028Holding current value
$20.6 Million% of portfolio
1.21%Shares
1 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$330 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$325 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$276 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$265 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$195 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...